Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 2
2020 3
2021 1
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
Pharmacodynamics of natalizumab extended interval dosing in MS.
Zhovtis Ryerson L, Li X, Goldberg JD, Hoyt T, Christensen A, Metzger RR, Kister I, Foley J. Zhovtis Ryerson L, et al. Neurol Neuroimmunol Neuroinflamm. 2020 Feb 4;7(2):e672. doi: 10.1212/NXI.0000000000000672. Print 2020 Mar. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 32019876 Free PMC article.
Outcomes of COVID-19 infection in multiple sclerosis and related conditions: One-year pandemic experience of the multicenter New York COVID-19 Neuroimmunology Consortium (NYCNIC).
Klineova S, Harel A, Straus Farber R, DeAngelis T, Zhang Y, Hentz R, Leung TM, Fong K, Smith T, Blanck R, Zhovtis-Ryerson L. Klineova S, et al. Among authors: zhovtis ryerson l. Mult Scler Relat Disord. 2021 Oct;55:103153. doi: 10.1016/j.msard.2021.103153. Epub 2021 Jul 19. Mult Scler Relat Disord. 2021. PMID: 34392059 Free PMC article.
Incomplete Susac syndrome exacerbated after natalizumab.
Zhovtis Ryerson L, Kister I, Snuderl M, Magro C, Bielekova B. Zhovtis Ryerson L, et al. Neurol Neuroimmunol Neuroinflamm. 2015 Sep 24;2(5):e151. doi: 10.1212/NXI.0000000000000151. eCollection 2015 Oct. Neurol Neuroimmunol Neuroinflamm. 2015. PMID: 26445727 Free PMC article. No abstract available.
Extended interval dosing of natalizumab in multiple sclerosis.
Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, Pandey K, Donnelly S, Pawate S, Bomprezzi R, Smith D, Kolb C, Qureshi S, Okuda D, Kalina J, Rimler Z, Green R, Monson N, Hoyt T, Bradshaw M, Fallon J, Chamot E, Bucello M, Beh S, Cutter G, Major E, Herbert J, Frohman EM. Zhovtis Ryerson L, et al. J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):885-9. doi: 10.1136/jnnp-2015-312940. Epub 2016 Feb 25. J Neurol Neurosurg Psychiatry. 2016. PMID: 26917698
COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center.
Parrotta E, Kister I, Charvet L, Sammarco C, Saha V, Charlson RE, Howard J, Gutman JM, Gottesman M, Abou-Fayssal N, Wolintz R, Keilson M, Fernandez-Carbonell C, Krupp LB, Zhovtis Ryerson L. Parrotta E, et al. Among authors: zhovtis ryerson l. Neurol Neuroimmunol Neuroinflamm. 2020 Jul 9;7(5):e835. doi: 10.1212/NXI.0000000000000835. Print 2020 Sep. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 32646885 Free PMC article.
Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.
Kister I, Patskovsky Y, Curtin R, Pei J, Perdomo K, Rimler Z, Voloshyna I, Samanovic MI, Cornelius AR, Velmurugu Y, Nyovanie S, Kim JJ, Tardio E, Bacon TE, Zhovtis Ryerson L, Raut P, Pedotti R, Hawker K, Raposo C, Priest J, Cabatingan M, Winger RC, Mulligan MJ, Krogsgaard M, Silverman GJ. Kister I, et al. Among authors: zhovtis ryerson l. Ann Neurol. 2022 Jun;91(6):782-795. doi: 10.1002/ana.26346. Epub 2022 Apr 1. Ann Neurol. 2022. PMID: 35289960 Free PMC article.